{"nctId":"NCT03373201","briefTitle":"Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia","startDateStruct":{"date":"2017-10-16","type":"ACTUAL"},"conditions":["Jet Lag Type Insomnia"],"count":320,"armGroups":[{"label":"Tasimelteon","type":"EXPERIMENTAL","interventionNames":["Drug: Tasimelteon"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tasimelteon","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability and acceptance to provide written consent, fluent in English;\n* Healthy subjects with no medical, psychiatric or current sleep disorders;\n* Men or women between 18-75 years;\n* Body Mass Index of ≥ 18 and ≤ 30 kg/m2.\n\nExclusion Criteria:\n\n* Major surgery, trauma, illness or immobile for 3 or more days within the past month;\n* Pregnancy or recent pregnancy (within 6 weeks);\n* A positive test for drugs of abuse at the screening or evaluation visit.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Sleep Time in the First Two Thirds of the Night","description":"Total sleep time during the first 2/3 of the night following an 8-hour phase advance bedtime, as measured by PSG. This is representative of trans meridian travel across 8 time zones.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156.1","spread":"80.67"},{"groupId":"OG001","value":"216.4","spread":"69.69"}]}]}]},{"type":"SECONDARY","title":"Total Sleep Time","description":"Total Sleep Time as measured by PSG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230.3","spread":"97.39"},{"groupId":"OG001","value":"315.8","spread":"95.51"}]}]}]},{"type":"SECONDARY","title":"Latency to Persistent Sleep","description":"Length of time elapsed between lights out and onset of persistent sleep as measure by PSG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":"63.56"},{"groupId":"OG001","value":"21.8","spread":"33.69"}]}]}]},{"type":"SECONDARY","title":"Wake After Sleep Onset","description":"The amount of wake time during the sleep period after sleep onset (as measured by polysomnography).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219.1","spread":"96.90"},{"groupId":"OG001","value":"144.6","spread":"86.73"}]}]}]},{"type":"SECONDARY","title":"Next Day Alertness as Measured by the Karolinska Sleepiness Scale (Night 1 Average Score)","description":"A 9-point scale that measures subjective levels of fatigue by asking how sleepy subjects feel at that moment: 1 = extremely awake to 9 =extremely sleepy/fighting to stay awake.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"1.86"},{"groupId":"OG001","value":"4.0","spread":"1.77"}]}]}]},{"type":"SECONDARY","title":"Next Day Alertness as Measured by the Visual Analogue Scale (Night 1 Average Score)","description":"The VAS was a self-rated scale to assess sleepiness. Participants marked along a 100 mm line to represent their current state of sleepiness, 0 being very sleepy and 100 being very alert. The VAS was administered four times following the dose administration after awakening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":"23.46"},{"groupId":"OG001","value":"60.8","spread":"22.24"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":160},"commonTop":["Headache"]}}}